Barzolvolimab (WT IgG1)
Based on 1 Customer Validation
Barzolvolimab (WT IgG1) (CDX-0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab (WT IgG1) specificity and potently inhibits KIT activation by SCF. Barzolvolimab (WT IgG1) can reduce skin mast cells and disease activity in chronic inducible urticaria.
For research use only. We do not sell to patients.
- Purity : 99.83%
- CAS No.: 2438203-51-9
- Molecular Weight:145.1 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
c-Kit/CD117
In Vitro
Barzolvolimab (WT IgG1) binds the extracellular domain of KIT with high specificity and sub-nanomolar affinity, and allosterically inhibits activation by stem cell factor (SCF)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD117/c-kit Protein, Human (HEK293, His, HY-P72752) can bind Barzolvolimab. The EC50 for this effect is 4.976 ng/mL. -
Flow cytometric analysis of 1.5×106 THP-1 cells labeling Barzolvolimab (HY-P99462, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Loaded Barzolvolimab on ProA biosensor, can bind CD117/c-kit Protein, Human (HEK293, His, HY-P72752) with an affinity constant of 1.128E-09 M as determined in BLI assay.
Chemical Information
-
CAS No. 2438203-51-9
-
Appearance Liquid
-
Molecular Weight 145.1 kDa
-
Color Colorless to light yellow
-
SMILES
[Barzolvolimab (WT IgG1)]
-
Synonyms
CDX-0159
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)